초록 ▼

The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endotheli

The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.

대표청구항 ▼

1. A method for inhibiting the early development of mammary cancer in a patient in need thereof, comprising administering a therapeutically effective amount of a selective endothelin B receptor (BTB) antagonist to said patient, with the provisio that said method does not include gene therapy. 2. The

1. A method for inhibiting the early development of mammary cancer in a patient in need thereof, comprising administering a therapeutically effective amount of a selective endothelin B receptor (BTB) antagonist to said patient, with the provisio that said method does not include gene therapy. 2. The method of claim 1, wherein the selective endothelin B receptor (ETB) antagonist is a peptide inhibitor. 3. The method of claim 1, wherein the selective endothelin B receptor (ETB) antagonist is an endothelin B receptor (ETB) antibody. 4. The method of claim 1, wherein the selective endothelin B receptor (ETB) antagonist is BQ788. 5. The method of claim 1, wherein the selective endothelin B receptor (ETB) antagonist is IRL-1038. 6. The method of claim 1, wherein the selective endothelin B receptor (ETB) antagonist is RES-701-1.